This research revealed the critical roles of lncRNA SBF2-AS1/miR-338-3p/ADAM17 axis in the growth and aggressive phenotypes of NSCLC, which might be served as a therapeutic target for NSCLC. The gene discussed is ADAM17; the disease is non-small cell lung carcinoma.